Fermata

Join Fermata and friends on Bluesky!

We offer SAINT at Fermata in NYC through an open label clinical trial and accept referral and inquires from all over the world!

???????????????????? ???? ???? ?????? ??????????????????! Thank you, Loren Larsen and Owen M. for sharing invaluable insights on ???????????????????? ??????????-?????????? ???????????????????? ?????? ???????????????????? ?????????????? ???????????????????? ?????? ?????????????? ???????????? ???????????? ?????????????????? at the #DHAI2024 ?#AIinHealthcare #MentalHealth #Innovation #DHAISummit

Highlights of #AACAP24 so far: Owen Muir MD DFAACAP Yesie Yoon MD Howie Levin, and I along with other colleagues became Distinguished Fellows, got to debate alongside Ashvin Sood, MD and Stephanie Hartselle MD on social media’s impact on mental health in adolescents to a packed room with Paul Weigle at the helm, spent time with some of my favorite powerhouse female mentors Cathryn Galanter, M.D. Alice Mao and Gabrielle Shapiro and of course Rob Grant has been kicking around making all the conference magic happen. Thanks American Academy of Child and Adolescent Psychiatry (AACAP) fam and looking forward to the rest of the week! ????????????????

We are very happy to announce that Fermata has partnered with BrainsWay on a new investigational TMS Study! This clinical trial is anticipated to enroll over 100 patients with major depressive disorder (MDD) who will be split into two groups – one receiving a novel accelerated treatment protocol featuring an acute phase?over several treatment days, and the other receiving the FDA-cleared standard-of-care protocol which entails an acute phase?over several weeks. In order to be eligible for the study, participants must: ? Be diagnosed with Major Depressive Disorder ? Be between 22-68 years old ? Have taken 1-4 antidepressants in the current depressive episode Full Inclusion/Exclusion criteria can be found on the clinical trials.gov link at the bottom of this post. The benefit to participants include: ? Receiving deep TMS treatment regardless of whether the participant is randomized into the standard-of-care or acute phase. ?It's free! If you are interested in referring someone for this study please fill out the inquiry form on our website, fermata.health. Owen Muir MD DFAACAP Carlene MacMillan, MD, FCTMSS,DFAACAP Aron Tendler Colleen Hanlon https://lnkd.in/ecfWwt-s

We are excited to be offering this treatment for PTSD at our practice! Psychedelics are not the only new promising treatment for PTSD.

We are proud of Amna M. Aslam, MBA, MSc and Carlene MacMillan, MD for representing Fermata so well at the APA and Horizons meetings!

NeuroSigma is honored to be part of the 2024 cohort for the largest pediatric digital health accelerator, @KidsX! Over the next 10 weeks, NeuroSigma will have the opportunity to accelerate our growth and work with the leading children’s hospitals and entrepreneurial innovators from the #KidsX network to make pediatric care exceptionally impactful, safe, and convenient for children and families. #kidsx #pediatrics #innovation #startups #accelerators #healthcare #entrepreneurs

Join our co-founders Carlene MacMillan, MD and Owen Muir MD DFAACAP tonight for this important presentation on how medical devices are transforming the field of psychiatry!